US 12257247
Targeted degradation of VAV1
granted A61KA61K31/4545A61P
Quick answer
US patent 12257247 (Targeted degradation of VAV1) held by Monte Rosa Therapeutics AG expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Monte Rosa Therapeutics AG
- Grant date
- Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K31/4545, A61P, A61P1/04, A61P19/02